In our efforts to develop novel metformin derivatives with increased potency for AMPK activation and mTOR inhibition, we found that the anti-cancer effects of metformin-butyrate (MFB) appeared to outperform those of metformin at lower doses. This evidence concerns the gene MTOR and cancer.